OncoSec Medical Announces $16 Million Registered Direct Offering

OncoSec Medical Inc. , a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $16 million of securities in a registered direct offering.



from Content Keyword RSS http://ift.tt/1kKMarT

via IFTTT